Skip to main content
Premium Trial:

Request an Annual Quote

Dolomite, Sphere Sign Agreement for Picodroplet Applications

NEW YORK (GenomeWeb) – UK-based microfluidics developer Dolomite will sell Sphere Fluidics' products under a distribution deal announced by the two firms this week.

The agreement covers Sphere's biochips, surfactants, and other specialty chemicals for picodroplet applications. Financial and other terms were not disclosed.

Also headquartered in the UK, Sphere develops products for single-cell analysis and characterization. Its technology platform enables the ultra high-throughput analysis of single cells and the generation of their genetic, transcriptomic, and proteomic profiles in miniaturized volumes, according to the company's website.

In a statement, Dolomite COO Lee Jeffries said that picodroplets are a fast-growing area of research "especially useful where tests need to be conducted on picoliters of samples containing, for example, single cells or biologically important molecules." The partnership between the two firms "will enable Dolomite to enhance our market leading microfluidic system solutions by offering unique capabilities in picodroplet generation, isolation, and analysis," he said.